ÂÜÀòÂÒÂ×

Henry Lowman has more than 30 years of experience in the research and development of biotherapeutics. After earning a B.A. in chemistry at Johns Hopkins University and a Ph.D. in chemistry at Purdue University, he was named an NIH postdoctoral fellow at Genentech. He then moved on to scientist roles, before leading Genentech’s antibody engineering department, with R&D team-leader roles in several therapeutic antibody programs, including VEGF, IgE, and CD20. He later served at CytomX Therapeutics as VP of research and CSO in work on the Probody™ platform, and at Triphase Accelerator as executive director/VP of R&D. In 2013, he was named one of the top 25 most influential individuals in the antibody field by Total Biopharma. Dr. Lowman is an editorial board member for the antibody journal mAbs and is currently an advisor/SAB member for several biotech organizations.